ALRTF
ALR TECHNOLOGIES SG LTD
stock OTC

Ticker $ALRTF: TLDR: You can't prick the finger of a dog or cat to test blood sugar like a human so ALRT is going to be rich from launching the first and only CGM for pets. Extremely low volume stock but there has never been any dilution since the CEO and his family fund the company. Only 217M share float and 645M O/S with $8M market cap so this one will fly when volume comes in with more news. Company has been quiet for the past two years while they built out manufacturing but news and sales should start flowing now.
Background story is ALRT formed the animal health division in 2022 and partnered with Covetrus who is the largest animal health distributor. They launched in 2023 and sold out but there was an issue with the manufacturer so they spent the last two years building out manufacturing with a new partner.
The PR talks about the market size being 5-6 million units and with Covetrus selling in the US and EU they will corner the market quickly since there is no competition. They also have a human division and so there is a lot more to come with a human CGM and their FDA cleared diabetes platform, patented predictive A1C, and FDA cleared insulin dose adjustment feature.
$8m market cap with no dilution makes this a great opportunity in my opinion even with very low volume.
Link to PR: [https://www.prnewswire.com/news-releases/alr-technologies-to-relaunch-the-glucurve-pet-cgm-in-january-2026-302635427.html](https://www.prnewswire.com/news-releases/alr-technologies-to-relaunch-the-glucurve-pet-cgm-in-january-2026-302635427.html)

Ticker $ALRTF: TLDR: You can't prick the finger of a dog or cat to test blood sugar like a human so ALRT is going to be rich from launching the first and only CGM for pets. Extremely low volume stock but there has never been any dilution since the CEO and his family fund the company. Only 217M share float and 645M O/S with $8M market cap so this one will fly when volume comes in with more news. Company has been quiet for the past two years while they built out manufacturing but news and sales should start flowing now.
Background story is ALRT formed the animal health division in 2022 and partnered with Covetrus who is the largest animal health distributor. They launched in 2023 and sold out but there was an issue with the manufacturer so they spent the last two years building out manufacturing with a new partner.
The PR talks about the market size being 5-6 million units and with Covetrus selling in the US and EU they will corner the market quickly since there is no competition. They also have a human division and so there is a lot more to come with a human CGM and their FDA cleared diabetes platform, patented predictive A1C, and FDA cleared insulin dose adjustment feature.
$8m market cap with no dilution makes this a great opportunity in my opinion even with very low volume.
Link to PR: [https://www.prnewswire.com/news-releases/alr-technologies-to-relaunch-the-glucurve-pet-cgm-in-january-2026-302635427.html](https://www.prnewswire.com/news-releases/alr-technologies-to-relaunch-the-glucurve-pet-cgm-in-january-2026-302635427.html)